secwatch.observer — SEC 8-K summary
======================================

Issuer:     Panbela Therapeutics, Inc. (—)
CIK:        0001029125
Form:       8-K
Filed at:   2023-04-18T23:59:59+00:00
Accession:  0001437749-23-010553
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 5.03, 3.01, 3.02, 3.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Panbela receives Nasdaq bid price deficiency notice; issues preferred stock with 100M votes to Chairman
--------------------------------------------------------------------------------

- Received Nasdaq notice: common stock bid price below $1.00 for 30 consecutive days; 180-day cure period until Oct 11, 2023.
- Issued 1 share of Series A Preferred Stock to Chairman Michael T. Cullen for $10; share carries 100M votes solely on reverse stock split proposals.
- Amended bylaws to reduce stockholder quorum from majority to one-third of voting power.
- Preferred stock is not convertible, has no dividend or liquidation rights; redeemable at $10 upon board order or stockholder approval of reverse split.
- Company warns no assurance of regaining compliance; may face delisting if not cured.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1029125/000143774923010553/0001437749-23-010553-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1029125/000143774923010553/pbla20230417_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-010553

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer